- Home
- CIM vs PRTA Comparison
CIM vs PRTA Comparison
Compare CIM & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- PRTA
- Stock Information
- Founded
- CIM 2007
- PRTA 2012
- Country
- CIM United States
- PRTA Ireland
- Employees
- CIM N/A
- PRTA N/A
- Industry
- CIM Real Estate Investment Trusts
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- PRTA Health Care
- Exchange
- CIM Nasdaq
- PRTA Nasdaq
- Market Cap
- CIM 965.2M
- PRTA 809.8M
- IPO Year
- CIM 2007
- PRTA N/A
- Fundamental
- Price
- CIM $12.61
- PRTA $7.81
- Analyst Decision
- CIM Hold
- PRTA Buy
- Analyst Count
- CIM 2
- PRTA 9
- Target Price
- CIM $16.00
- PRTA $54.57
- AVG Volume (30 Days)
- CIM 533.6K
- PRTA 1.2M
- Earning Date
- CIM 05-08-2025
- PRTA 05-08-2025
- Dividend Yield
- CIM 11.56%
- PRTA N/A
- EPS Growth
- CIM N/A
- PRTA N/A
- EPS
- CIM 1.52
- PRTA N/A
- Revenue
- CIM $326,755,000.00
- PRTA $135,157,000.00
- Revenue This Year
- CIM $11.59
- PRTA N/A
- Revenue Next Year
- CIM $2.13
- PRTA $131.71
- P/E Ratio
- CIM $8.43
- PRTA N/A
- Revenue Growth
- CIM 11.90
- PRTA 47.92
- 52 Week Low
- CIM $9.85
- PRTA $8.00
- 52 Week High
- CIM $16.89
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- CIM 56.82
- PRTA 28.81
- Support Level
- CIM $11.96
- PRTA $9.37
- Resistance Level
- CIM $13.28
- PRTA $8.80
- Average True Range (ATR)
- CIM 0.34
- PRTA 0.67
- MACD
- CIM 0.16
- PRTA -0.07
- Stochastic Oscillator
- CIM 67.13
- PRTA 24.92
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).